Cutter & Co Brokerage’s Lifecore Biomedical LFCR Stock Holding History

Cutter & Co Brokerage’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,334	Closed	-$63.3K	–	224
2024 Q2	$63.3K	Buy	12,334 +1,567	+15%	+$9.28K	0.02%	198
2024 Q1	$57.2K	Sell	10,767 -4,800	-31%	-$34.3K	0.01%	200
2023 Q4	$96.4K	Sell	15,567 -6,133	-28%	-$42.6K	0.03%	187
2023 Q3	$164K	Hold	21,700	–	–	0.05%	187
2023 Q2	$210K	Hold	21,700	–	–	0.06%	186
2023 Q1	$81.9K	Hold	21,700	–	–	0.03%	204
2022 Q4	$141K	Sell	21,700 -6,800	-24%	-$56K	0.05%	199
2022 Q3	$253K	Hold	28,500	–	–	0.09%	164
2022 Q2	$284K	Sell	28,500 -200	-0.7%	-$1.98K	0.1%	166
2022 Q1	$332K	Hold	28,700	–	–	0.1%	155
2021 Q4	$319K	Sell	28,700 -3,500	-11%	-$34K	0.09%	182
2021 Q3	$297K	Hold	32,200	–	–	0.07%	214
2021 Q2	$362K	Hold	32,200	–	–	0.08%	193
2021 Q1	$341K	Hold	32,200	–	–	0.08%	194
2020 Q4	$349K	Hold	32,200	–	–	0.09%	174
2020 Q3	$313K	Hold	32,200	–	–	0.09%	165
2020 Q2	$256K	Buy	+32,200	New	+$332K	0.08%	173
2020 Q1	–	Sell	-32,200	Closed	-$364K	–	271
2019 Q4	$364K	Hold	32,200	–	–	0.13%	148
2019 Q3	$350K	Sell	32,200 -500	-2%	-$5.44K	0.11%	183
2019 Q2	$306K	Hold	32,700	–	–	0.1%	213
2019 Q1	$402K	Sell	32,700 -200	-0.6%	-$2.44K	0.11%	167
2018 Q4	$390K	Hold	32,900	–	–	0.15%	148
2018 Q3	$474K	Buy	32,900 +1,000	+3%	+$13.8K	0.16%	133
2018 Q2	$475K	Hold	31,900	–	–	0.18%	125
2018 Q1	$416K	Buy	31,900 +6,800	+27%	+$89.4K	0.16%	133
2017 Q4	$316K	Sell	25,100 -6,800	-21%	-$85.9K	0.13%	153
2017 Q3	$413K	Sell	31,900 -500	-2%	-$6.59K	0.16%	128
2017 Q2	$481K	Hold	32,400	–	–	0.19%	126
2017 Q1	$389K	Buy	32,400 +3,600	+13%	+$45.6K	0.16%	133
2016 Q4	$397K	Hold	28,800	–	–	0.16%	128
2016 Q3	$386K	Sell	28,800 -700	-2%	-$8.48K	0.17%	117
2016 Q2	$317K	Hold	29,500	–	–	0.14%	142
2016 Q1	$310K	Hold	29,500	–	–	0.14%	144
2015 Q4	$349K	Hold	29,500	–	–	0.16%	130
2015 Q3	$344K	Hold	29,500	–	–	0.17%	123
2015 Q2	$426K	Hold	29,500	–	–	0.17%	145
2015 Q1	$412K	Sell	29,500 -1,800	-6%	-$24.9K	0.17%	128
2014 Q4	$432K	Sell	31,300 -4,400	-12%	-$56.9K	0.16%	133
2014 Q3	$437K	Hold	35,700	–	–	0.17%	131
2014 Q2	$446K	Hold	35,700	–	–	0.16%	136
2014 Q1	$398K	Buy	35,700 +4,000	+13%	+$43.9K	0.16%	139
2013 Q4	$384K	Hold	31,700	–	–	0.18%	124
2013 Q3	$387K	Buy	31,700 +2,500	+9%	+$34.9K	0.17%	132
2013 Q2	$386K	Buy	+29,200	New	+$404K	0.18%	126

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutter & Co Brokerage's LFCR Position: Q3 2024 in Review

Cutter & Co Brokerage sold out of Lifecore Biomedical (LFCR) in Q3 2024, closing a stake of 12,334 shares — an estimated $63.3K sold.

Cutter & Co Brokerage first reported a position in LFCR in Q2 2013 and held it in 44 quarters. The position peaked at $481K in Q2 2017. 82 funds tracked by Wall St. Rank hold LFCR as of Q3 2024.

Cutter & Co Brokerage reported no remaining Lifecore Biomedical position as of Q3 2024 after selling out during the quarter.
Cutter & Co Brokerage sold 12,334 Lifecore Biomedical shares in Q3 2024, an estimated $63.3K.
Cutter & Co Brokerage first reported a position in Lifecore Biomedical in Q2 2013 and held it in 44 quarters.
Cutter & Co Brokerage's Lifecore Biomedical position peaked at $481K in Q2 2017.
82 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2024.

Based on Cutter & Co Brokerage's 13F filing for Q3 2024, filed 25 Oct 2024.